Preview

Медицинский Совет

Расширенный поиск

Короткие курсы антибактериальной терапии внебольничной пневмонии у взрослых. Лучше меньше, да лучше

https://doi.org/10.21518/2079-701X-2018-15-124-130

Полный текст:

Аннотация

Несмотря на достигнутые успехи в диагностике, терапии и профилактике инфекций дыхательных путей, внебольничная пневмония (ВП) остается достаточно распространенным заболеванием [1–3], сохраняя статус ведущей инфекционной причины смерти современного человека и унося ежегодно больше жизней, чем туберкулез, менингит, СПИД и инфекционный эндокардит вместе взятые [4]. При этом, очевидно, наиболее действенным инструментом в достижении лучшего исхода ВП являются клинические рекомендации, декларирующие в т. ч. и подходы к рациональной эмпирической антибактериальной терапии (АБТ) заболевания [5–8]. Однако вопрос об определении оптимальной продолжительности АБТ остается предметом оживленных дискуссий (табл. 1). Здесь важно отметить, что в большинстве случаев клинической стабильности больных ВП удается добиться уже в первые 3–5 дней эмпирической АБТ, и редко когда возникает необходимость в продолжительном назначении антибиотиков [12].

Об авторе

А. И. Синопальников
ГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия

Синопальников Александр Игоревич – доктор медицинских наук, профессор.

Москва



Список литературы

1. Prina E, Ranzani OT, Torres A. Communityacquired pneumonia. Lancet, 2015, 386: 10971108.

2. Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med, 2009, 30: 127-135.

3. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax, 2013, 68: 1057-1065.

4. Hoyert DL, Xu J. Death: preliminary data for 2011. Natl Vital Stat Rep, 2012, 61: 1-51.

5. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med, 2014, 370: 543-551.

6. Han X, Zhou F, Li H, et al. Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with communityacquired pneumonia. BMC Infect Dis, 2018, 18: 192.

7. Huijts SM, van Werkhoven CH, Boersma WG, et al. Guideline adherence for empirical treatment of pneumonia and patient outcome. Treating pneumonia in the Netherlands. Neth J Med, 2013, 71: 502-507.

8. Dambrava PG, Torres A, Valles X, et al. Adherence guidelines empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J, 2008, 32: 892-901.

9. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/ American thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis, 2007, 44(Suppl 2): S27-S72.

10. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect, 2011, 17: 1-24.

11. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community-acquired pneumonia in adults: update 2009. Thorax, 2009, 64: 1-55.

12. Navarta AC, Peyrani P, Wiemken TL, et al. Short duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study. ULJRI, 2017, 1: 21-26.

13. Hanretty AM, Gallagher JC. Shortened courses of antibiotics for bacterial infections: A systematic review of randomized controlled trials. Pharmacotherapy, 2018, 38: 674-687.

14. Tansarli GS, Mylonakis EE. Efficacy of shortcourse antibiotic treatments for communityacquired pneumonia in adults: A systematic review and meta-analysis. Antimicrob Agents Chemother, 2018. doi:10.1128/AAC.00635-18.

15. Bronzawear SLAM, Cars O, Udo Buchholz SM, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis, 2002, 8: 278-282.

16. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet, 2005, 365: 579-587.

17. Esposito S, Esposito I, Leone S. Considerations of antibiotic therapy duration in community- and hospital-acquired bacterial infections. J Antimicrob Chemother, 2012, 67: 2570-2575.

18. Guillemont D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of betalactam: risk factors for carriage of penicillinresistant Streptococcus pneumoniae. JAMA, 1998, 279: 365-370.

19. File TM Jr. Clinical efficacy of newer agents in short-duration therapy for communityacquired pneumonia. Clin Infect Dis, 2004, 39: 159-164.

20. Scalera NM, File TM Jr. How long should we treat community-acquired pneumonia? Curr Opin Infect Dis, 2007, 20: 177-181.

21. Andes D, Craig WA. Animal model pharmacokinetics and pharmaco-dynamics: a clinical review. Int J Antimicrob Agents, 2002, 19: 261268.

22. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis, 1998, 26: 1-10.

23. Cecil RL, McDermott W, editors. Textbook of medicine. 7th ed. Philadelphia: WB Saunders Co., 1948.

24. Harrison TR, Resnick WR, Wintrobe MM, et al., editors. Principles of internal medicine. 5th ed. New York: McGraw Hill, 1967.

25. Witt RL, Hamburger M. The nature and treatment of pneumococcal pneumonia. Med Clin North Am, 1963, 47: 1257-1270.

26. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA, 1998, 279: 14521457.

27. Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol, 1979, 73: 235-240.

28. Uranga A, Espana PP, Bilbao A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med, 2016, 176: 1257-1265.

29. Royer S, DeMerle KM, Dickson RP, Prescott HC. Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis. J Hosp Med, 2018, 13: 336-342.

30. O’Doherty B, Muller O and azithromycin study group. Randomized, multicenter study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur J Clin Microbiol Infect Dis, 1998, 17: 828-833.

31. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther, 1999, 6: 217-222.

32. Leophonte P, Choutet P, Gaillat J, et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med Mal Infect, 2002, 32: 369-381.

33. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis, 2003, 37: 752-760.

34. Dunbar LM, Khashab MM, Kahn JB, et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin, 2004, 20: 555-563.

35. Tellier G, Chang JR, Asche CV, et al. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Curr Med Res Opin, 2004, 20: 739747.

36. Drehobl MA, De Salvo MC, Lewi DE, Breen JD. Single-dose azithromycin microspheres vs. clarithromycin extended release for the treatment of mild to moderate community-acquired pneumonia in adults. Chest, 2005, 128: 22302237.

37. El Moussaoui R, de Borgie CAJM, van Den Broek P. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate -severe community-acquired pneumonia: randomized, double blind study. BMJ, 2006, 332: 1355.

38. File TMJr, Mandell LA, Tillotson G, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicenter, doubleblind study. J Antimicrob Chemother, 2007, 60: 112-120.

39. Baldwin DR, Wise R, Andrews JM, et al. Azithromycin-concentrations at the sites of pulmonary infection. Eur Resp J, 1990, 3: 886890.

40. Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and 3-day course. J Chemother, 1998, 10: 64-68.

41. O’Doherty B, Muller O, and azithromycin study group. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur J Clin Microbiol Infect Dis, 1998, 17: 828-833.

42. Sopena N, Martinez-Vazquez C, RodriguesSuarez JR, et al. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of communityacquired pneumonia in adults. J Chemother, 2004, 16: 102-103.

43. D’Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for reatment of mild to moderate communityacquired pneumonia in adults. Antimicrob Agents Chemother, 2005, 49: 4035-4041.

44. Okayasu S, Matsuura K, Kondoh Y, et al. A survey on diarrhea and convenience of intake associated with a single-dose extended release formulation of azithromycin. Pharmazie, 2011, 66: 226-229.

45. File TM Jr. A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia. Clinical Cornerstone, 2003, Suppl 3: 21-28.

46. Zelenitsky SA, Ariano RE, Iacovides H, et al. AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. О Antimicrob Chemother, 2003, 51: 905-911.

47. Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med, 2006, 100: 2129-2136.

48. Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥ 65 years with community-acquired pneumonia. Clin Ther, 2005, 27: 1251-1259.

49. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high doses amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA, 2001, 286: 49-56.

50. Tansarli GS, Mylonakis EE. Efficacy of shortcourse antibiotic treatment for communityacquired pneumonia in adults: A systematic review and meta-analysis. Antimicrob Agents Chemother, 2018. doi:10.1128/AAC. 00635-18.

51. Kaziani K, Sotiriou A, Dimopoulos G. Duration of pneumonia therapy and the role of biomarkers. Curr Opin Infect Dis, 2017, 30: 221-225.

52. Albrich WS, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”. An international, multicenter poststudy survey (proreal). Arch Intern Med, 2012, 172: 715-722.

53. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled study. JAMA, 2009, 302: 1059-1066.

54. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med, 2006, 174: 84-93.

55. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA, 2009, 302: 1059-1066.

56. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, singleblinded intervention trial. Lancet, 2004, 363: 600-607.

57. De Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin in guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomized, controlled, open-label trial. Lancet Infect Dis, 2016, 16: 819-827.

58. Muller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest, 2010, 138: 121-129.

59. Kruger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with cap: Results from the German competence network CAPNETZ. Respir Res, 2009, 10: 65.

60. Kruger S, Ewig S, Kunde J, et al. Assessment of inflammatory markers in patients with community-acquired pneumonia-Influence of antimicrobial pre-treatment results from the German competence network CAPNETZ. Clin Chim Acta, 2010, 411: 1929–1934.

61. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis. Crit Care Med, 2006, 34: 1996-2003.

62. Hunziker S, Hugle T, Schuchardt K, et al. The value of serum procalcitonin level for differentiation of infectious from noninfectious causes of fever after orthopedic surgery. J Bone Joint Surg Am, 2010, 92: 138-148.

63. Sponholz C, Sakr Y, Reinhart K, Brunkhorst F. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: A systematic review of the literature. Crit Care, 2006, 10: R145.

64. Wiersinga W, Bonten MJ, Boersma WG, et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth J Med, 2018, 76: 4–13.

65. Nair GB, Niederman MS. Community-acquired pneumonia: an unfinished battle. Med Clin N Amer, 2011, 95: 1143-1161.

66. Montassier E, Goffinet N, Potel G, Batard E. How to reduce antibiotic consumption for community-acquired pneumonia? Med Malad Infect, 2013, 43: 52-59.


Просмотров: 87


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)